Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Skin Neoplasms 2Thymic aplasia 1Prostatic Neoplasms 1Lymphoma, Follicular 1Immunologic Deficiency Syndromes 1Erectile Dysfunction 1Dermatitis, Atopic 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 9gadolinium ethoxybenzyl DTPA 4Hepatectomy 4lenvatinib 3entecavir 3Sufentanil 3Ribavirin 3Propranolol 3Lamivudine 3sofosbuvir-velpatasvir drug combination 2peginterferon alfa-2a 2gadoterate meglumine 2atezolizumab 2Thrombectomy 2Tenofovir 2Sevoflurane 2Radiofrequency Ablation 2Laparoscopy 2Esketamine 2Chemoembolization, Therapeutic 2Bevacizumab 2xihuang 1stronger neominophagen C 1ledipasvir 1huaier 1halofantrine 1gadoteridol 1gadodiamide 1gadobutrol 1gadobenic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Hepatocellular × Tacrolimus × Clear all
NCT02081755 2026-01-27

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Baylor Research Institute

Phase 4 Enrolling by invitation
336 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡